CRBD — Corebridge Financial, Inc.

NYSE · Financials · Insurance · CIK 1889539 ·
Last close
$21.86
Market Cap
52W High
$23.28
52W Low
$21.76
ADV30
39,893
Next earnings
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2024 2,599,000,000 2,599,000,000 1,951,000,000 -1,184,000,000 389,397,000,000 806,000,000 377,071,000,000
Dec 2023 5,505,000,000 5,505,000,000 4,786,000,000 2,101,000,000 379,270,000,000 612,000,000 366,635,000,000
Dec 2021 5,521,000,000 5,521,000,000 4,876,000,000 1,420,000,000 416,212,000,000 537,000,000 387,284,000,000
Dec 2020 6,538,000,000 6,538,000,000 5,683,000,000 2,406,000,000 422,435,000,000 552,000,000 383,760,000,000

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2024 18,800,000,000 16,342,000,000 1,104,000,000 389,397,000,000 377,071,000,000
Dec 2023 24,697,000,000 21,213,000,000 8,159,000,000 379,270,000,000 366,635,000,000
Dec 2021 15,062,000,000 11,611,000,000 642,000,000 416,212,000,000 387,284,000,000
Dec 2020 23,257,000,000 22,603,000,000 8,243,000,000 422,435,000,000 383,760,000,000

TTM Snapshot

Revenues TTM
$16,208,000,000
NetIncome TTM
$1,834,000,000
OpCashFlow TTM
$0
Assets (Latest)
$389,397,000,000
Forward EPS

Peers — same industry

TickerNameMarket CapLastDaily %
BRK-B BERKSHIRE HATHAWAY INC $710.10B $504.32
UNH UNITEDHEALTH GROUP INC $357.92B $398.76
CB Chubb Ltd $133.42B $345.83
PGR PROGRESSIVE CORP/OH/ $130.18B $223.92
MRSH MARSH & MCLENNAN COMPANIES, INC. $92.90B $194.67

Recent Insider Activity

No insider activity indexed for this ticker.